Enlivex Therapeutics Ltd. ( ENLV) - Key Metrics
ENLV Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | $114.36 | -$0.33 | -$0.33 |
| 2026Q1 | $0 | $54.25 | -$0.30 | -$0.30 |
| 2025Q4 | $0 | $410.29 | -$0.96 | -$0.96 |
| 2025Q3 | $0 | -$1.38 | -$1.23 | -$1.45 |
| 2025Q2 | $0 | -$1.17 | -$0.75 | -$0.76 |
ENLV Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | 0.02 |
| 2026Q1 | 0% | 0.06 |
| 2025Q4 | 0% | 0.01 |
| 2025Q3 | 0% | -2.83 |
| 2025Q2 | 0% | -3.59 |
ENLV
Price: $1.44
52 week price:
Earnings Per Share: 415.39 USD
P/E Ratio: 0.00
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: Israel
Volume: 21300
Market Capitalization: 23.7 million